Singulex's vision is to transform chronic disease management, improving patient care and health while reducing healthcare costs. Singulex's proprietary SMC platform significantly increases the diagnostic and prognostic power of established biomarkers. This enables physicians to individualize treatment strategies, monitor effectiveness of therapy and encourage patient adherence through feedback. Improved patient outcomes and the reduced need for costly, invasive diagnostic procedures translate into healthcare cost savings. The Singulex CLIA-certified laboratory offers a comprehensive menu of advanced cardiovascular disease testing to physicians in the U.S. At leading pharmaceutical R&D laboratories, academic institutions and clinical research organizations (CROs) around the world, Singulex's SMC technology is powering discovery and development of innovative diagnostics and treatments for chronic diseases such as cardiovascular disease, Alzheimer's, arthritis and diabetes. For further information, visit www.singulex.com.

Key Contact